Skip to main content
Smart Investors Daily
HY

NASDAQ · HYPMY

Hypera S.A.

Healthcare · Drug Manufacturers - Specialty & Generic

$4.32

Down-$0.03 (-0.69%)

Updated Aug 27, 2026, 4:56 PM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
2.78B
P/E ratio
18.24
Dividend yield
4.77%
52-week range
— – —
Volume
2.09K
Avg. volume
9.02K

Price performance

HYPMY price history

1M range · 0 trading sessions · Daily adjusted prices

HYPMY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest HYPMY news

The latest Smart Investors Daily articles mentioning HYPMY.

HYPMY research

Overview

Company profile and research snapshot.

Company profile

HYPERA SA S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.32
Implied upside
Analysts
19
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Oct 29, 2025

Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript

Hypera S.A. (OTCPK:HYPMY) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Breno Pires de Oliveira - Chief Executive Officer Ramon Frutuoso Silva - CFO & Investor Relation Officer Conference Call Participants Mauricio Cepeda - Morgan Stanley, Research Division Robert Ford - BofA Securities, Research Division Gustavo Miele - Goldman Sachs Group, Inc., Research Division Lucca Marquezini - Itaú Corretora de Valores S.A.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.